Lisa Delfini Biography and Net Worth

CFO of Trevi Therapeutics

Lisa Delfini has served as our Chief Financial Officer since August 2021. Ms. Delfini served as a Financial Accounting and Advisory Services Partner at Marcum LLP, an accounting and advisory services company, from 2015 until August 2021, specializing in providing services to companies in the life science and high-tech industries. Previously, she worked at General Electric Company, a multinational conglomerate, as Global Controller for the GE Corporate Technical Center of Excellence from 2011 to 2014 and as Global Controller for the GE Industrial Solutions division from 2014 to 2015. Ms. Delfini began her career at Deloitte & Touche LLP, where she worked for 16 years, completing her time there as a Client Service Partner. Ms. Delfini received a B.S. in accounting from Lehigh University and is a Certified Public Accountant licensed by the state of Connecticut.

What is Lisa Delfini's net worth?: The estimated net worth of Lisa Delfini is at least $717.67 thousand as of May 22nd, 2024. Ms. Delfini owns 53,279 shares of Trevi Therapeutics stock worth more than $717,668 as of December 5th. This net worth approximation does not reflect any other assets that Ms. Delfini may own. Learn More about Lisa Delfini's net worth.
How old is Lisa Delfini?: Ms. Delfini is currently 54 years old. There are 5 older executives and no younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics is Dr. Thomas R. Sciascia M.D., Co-Founder & Chief Science Officer, who is 71 years old. Learn More on Lisa Delfini's age.
How do I contact Lisa Delfini?: The corporate mailing address for Ms. Delfini and other Trevi Therapeutics executives is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. Trevi Therapeutics can also be reached via phone at (203) 304-2499 and via email at [email protected]. Learn More on Lisa Delfini's contact information.
Has Lisa Delfini been buying or selling shares of Trevi Therapeutics?: Lisa Delfini has not been actively trading shares of Trevi Therapeutics during the past quarter. Most recently, Lisa Delfini sold 4,350 shares of the business's stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $2.64, for a transaction totalling $11,484.00. Following the completion of the sale, the chief financial officer now directly owns 53,279 shares of the company's stock, valued at $140,656.56. Learn More on Lisa Delfini's trading history.
Who are Trevi Therapeutics' active insiders?: Trevi Therapeutics' insider roster includes Lisa Delfini (CFO), Jennifer Good (Co-Founder, President and CEO), David Meeker (Director), Thomas Sciascia (Co-Founder, Chief Scientific Officer), and Farrell Simon (Insider). Learn More on Trevi Therapeutics' active insiders.
Are insiders buying or selling shares of Trevi Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 86,576 shares worth more than $583,493.29. The most recent insider tranaction occured on March, 21st when CEO Jennifer L Good sold 5,263 shares worth more than $34,630.54. Insiders at Trevi Therapeutics own 18.3% of the company. Learn More about insider trades at Trevi Therapeutics.
Information on this page was last updated on 3/21/2025.

Lisa Delfini Insider Trading History at Trevi Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/22/2024	Sell	4,350	$2.64	$11,484.00	53,279
10/11/2023	Sell	785	$2.02	$1,585.70	35,901
9/11/2023	Sell	711	$2.20	$1,564.20	34,394
8/11/2023	Sell	682	$2.36	$1,609.52	32,814
7/11/2023	Sell	687	$2.34	$1,607.58	31,204
6/12/2023	Sell	610	$2.64	$1,610.40	29,599
4/11/2023	Sell	840	$1.84	$1,545.60	26,189
3/13/2023	Sell	892	$1.75	$1,561.00	24,737
2/13/2023	Sell	8,474	$2.45	$20,761.30	23,338

Lisa Delfini Buying and Selling Activity at Trevi Therapeutics

Trevi Therapeutics Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $13.47

$13.35

$14.00

50 Day Range

MA: $10.97

$8.77

$13.70

2 Week Range

Now: $13.47

$2.36

$14.00

Volume

2,803,945 shs

Average Volume

1,989,890 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Lisa Delfini Biography and Net Worth

What is Lisa Delfini's net worth?

How old is Lisa Delfini?

How do I contact Lisa Delfini?

Has Lisa Delfini been buying or selling shares of Trevi Therapeutics?

Who are Trevi Therapeutics' active insiders?

Are insiders buying or selling shares of Trevi Therapeutics?